Related references
Note: Only part of the references are listed.Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide
Jinfang Jiang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Clinical Pharmacokinetic Studies of Enzalutamide
Jacqueline A. Gibbons et al.
CLINICAL PHARMACOKINETICS (2015)
Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
Vincent C. O. Njar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, Synthesis, and Biological Evaluation of Deuterated C-Aryl Glycoside as a Potent and Long-Acting Renal Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes
Ge Xu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
Mark Sanford
DRUGS (2013)
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer
Kevin D. Courtney et al.
CURRENT OPINION IN ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs
Raman Sharma et al.
DRUG METABOLISM AND DISPOSITION (2012)
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
Nicholas A. Meanwell
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The changing therapeutic landscape of castration-resistant prostate cancer
Timothy A. Yap et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
Michael E. Jung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Karen E. Knudsen et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Gerhardt Attard et al.
CANCER CELL (2009)
International epidemiology of prostate cancer: Geographical distribution and secular trends
Peter D. Baade et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Targeting the androgen receptor pathway in prostate cancer
Yu Chen et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Androgen receptor: role and novel therapeutic prospects in prostate cancer
Mary-Ellen Taplin
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
HI Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
VD Handratta et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
The use of deuterium isotope effects to probe the active site properties, mechanism of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity
SD Nelson et al.
DRUG METABOLISM AND DISPOSITION (2003)
Isotopic effect study of propofol deuteration on the metabolism, activity, and toxicity of the anesthetic
J Helfenbein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Share Paper
